Suzanne Schuh1,2, Judy Sweeney1, Maggie Rumantir1, Allan L Coates3, Andrew R Willan4,5, Derek Stephens6, Eshetu G Atenafu7, Yaron Finkelstein2,8, Graham Thompson9,10, Roger Zemek11,12, Amy C Plint11,12, Jocelyn Gravel13,14, Francine M Ducharme13,14, David W Johnson15,16, Karen Black17, Sarah Curtis18, Darcy Beer19,20, Terry P Klassen21,20, Darcy Nicksy22, Stephen B Freedman23. 1. Division of Pediatric Emergency Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 2. Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 3. Division of Respiratory Medicine, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 4. Ontario Child Health Support Unit, SickKids Research Institute, Toronto, Ontario, Canada. 5. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 6. Research Institute, Clinical Research Services, The Hospital for Sick Children, Toronto, Ontario, Canada. 7. Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 8. Divisions of Pediatric Emergency Medicine and Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 9. Departments of Pediatrics and Emergency Medicine, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada. 10. Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada. 11. Department of Pediatrics and Emergency Medicine, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada. 12. CHEO Research Institute, Ottawa, Ontario, Canada. 13. Department of Pediatric Emergency Medicine, CHU Sainte-Justine, Montréal, Quebec, Canada. 14. Department of Pediatrics and of Social and Preventive Medicine, Université de Montréal, Montréal, Quebec, Canada. 15. Departments of Pediatrics, Emergency Medicine, and Physiology & Pharmacology, Alberta Children's Hospital, Calgary, Alberta, Canada. 16. Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 17. Division of Pediatric Emergency Medicine, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. 18. Departments of Pediatrics and Emergency Medicine, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada. 19. Pediatrics/Pediatric Emergency Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 20. Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada. 21. Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada. 22. Pharmacy Department, The Hospital for Sick Children, Toronto, Ontario, Canada. 23. Sections of Pediatric Emergency Medicine and Gastroenterology, Departments of Pediatrics and Emergency Medicine, Alberta Children's Hospital, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Abstract
Importance: While intravenous magnesium decreases hospitalizations in refractory pediatric acute asthma, it is variably used because of invasiveness and safety concerns. The benefit of nebulized magnesium to prevent hospitalization is unknown. Objective: To evaluate the effectiveness of nebulized magnesium in children with acute asthma remaining in moderate or severe respiratory distress after initial therapy. Design, Setting, and Participants: A randomized double-blind parallel-group clinical trial from September 26, 2011, to November 19, 2019, in 7 tertiary-care pediatric emergency departments in Canada. The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with anoral corticosteroid and 3 inhaled albuterol and ipratropium treatments. Of 5846 screened patients, 4332 were excluded for criteria, 273 declined participation, 423 otherwise excluded, 818 randomized, and 816 analyzed. Interventions: Participants were randomized to 3 nebulized albuterol treatments with either magnesium sulfate (n = 410) or 5.5% saline placebo (n = 408). Main Outcomes and Measures: The primary outcome was hospitalization for asthma within 24 hours. Secondary outcomes included PRAM score; respiratory rate; oxygen saturation at 60, 120, 180, and 240 minutes; blood pressure at 20, 40, 60, 120, 180, and 240 minutes; and albuterol treatments within 240 minutes. Results: Among 818 randomized patients (median age, 5 years; 63% males), 816 completed the trial (409 receivedmagnesium; 407, placebo). A total of 178 of the 409 children who received magnesium (43.5%) were hospitalized vs 194 of the 407 who receivedplacebo (47.7%) (difference, -4.2%; absolute risk difference 95% [exact] CI, -11% to 2.8%]; P = .26). There were no significant between-group differences in changes from baseline to 240 minutes in PRAM score (difference of changes, 0.14 points [95% CI, -0.23 to 0.50]; P = .46); respiratory rate (0.17 breaths/min [95% CI, -1.32 to 1.67]; P = .82); oxygen saturation (-0.04% [95% CI, -0.53% to 0.46%]; P = .88); systolic blood pressure (0.78 mm Hg [95% CI, -1.48 to 3.03]; P = .50); or mean number of additional albuterol treatments (magnesium: 1.49, placebo: 1.59; risk ratio, 0.94 [95% CI, 0.79 to 1.11]; P = .47). Nausea/vomiting or sore throat/nose occurred in 17 of the 409 children who received magnesium (4%) and 5 of the 407 who received placebo (1%). Conclusions and Relevance: Among children with refractory acute asthma in the emergency department, nebulized magnesium with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitalization rate for asthma within 24 hours. The findings do not support use of nebulized magnesium with albuterol among children with refractory acute asthma. Trial Registration: ClinicalTrials.gov Identifier: NCT01429415.
RCT Entities:
Importance: While intravenous magnesium decreases hospitalizations in refractory pediatric acute asthma, it is variably used because of invasiveness and safety concerns. The benefit of nebulized magnesium to prevent hospitalization is unknown. Objective: To evaluate the effectiveness of nebulized magnesium in children with acute asthma remaining in moderate or severe respiratory distress after initial therapy. Design, Setting, and Participants: A randomized double-blind parallel-group clinical trial from September 26, 2011, to November 19, 2019, in 7 tertiary-care pediatric emergency departments in Canada. The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments. Of 5846 screened patients, 4332 were excluded for criteria, 273 declined participation, 423 otherwise excluded, 818 randomized, and 816 analyzed. Interventions: Participants were randomized to 3 nebulized albuterol treatments with either magnesium sulfate (n = 410) or 5.5% saline placebo (n = 408). Main Outcomes and Measures: The primary outcome was hospitalization for asthma within 24 hours. Secondary outcomes included PRAM score; respiratory rate; oxygen saturation at 60, 120, 180, and 240 minutes; blood pressure at 20, 40, 60, 120, 180, and 240 minutes; and albuterol treatments within 240 minutes. Results: Among 818 randomized patients (median age, 5 years; 63% males), 816 completed the trial (409 received magnesium; 407, placebo). A total of 178 of the 409 children who received magnesium (43.5%) were hospitalized vs 194 of the 407 who received placebo (47.7%) (difference, -4.2%; absolute risk difference 95% [exact] CI, -11% to 2.8%]; P = .26). There were no significant between-group differences in changes from baseline to 240 minutes in PRAM score (difference of changes, 0.14 points [95% CI, -0.23 to 0.50]; P = .46); respiratory rate (0.17 breaths/min [95% CI, -1.32 to 1.67]; P = .82); oxygen saturation (-0.04% [95% CI, -0.53% to 0.46%]; P = .88); systolic blood pressure (0.78 mm Hg [95% CI, -1.48 to 3.03]; P = .50); or mean number of additional albuterol treatments (magnesium: 1.49, placebo: 1.59; risk ratio, 0.94 [95% CI, 0.79 to 1.11]; P = .47). Nausea/vomiting or sore throat/nose occurred in 17 of the 409 children who received magnesium (4%) and 5 of the 407 who received placebo (1%). Conclusions and Relevance: Among children with refractory acute asthma in the emergency department, nebulized magnesium with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitalization rate for asthma within 24 hours. The findings do not support use of nebulized magnesium with albuterol among children with refractory acute asthma. Trial Registration: ClinicalTrials.gov Identifier: NCT01429415.
Authors: Michael D Johnson; Joseph J Zorc; Douglas S Nelson; Theron Charles Casper; Lawrence J Cook; Yaron Finkelstein; Lynn Babcock; Lalit Bajaj; James M Chamberlain; Robert W Grundmeier; Michael Webb; Elizabeth R Alpern Journal: J Pediatr Date: 2020-03-05 Impact factor: 4.406
Authors: Donald H Arnold; Wu Gong; James W Antoon; Leonard B Bacharier; Thomas G Stewart; David P Johnson; Wendell S Akers; Tina V Hartert Journal: J Allergy Clin Immunol Pract Date: 2021-12-13
Authors: Simon Craig; Colin V E Powell; Gillian M Nixon; Ed Oakley; Jason Hort; David S Armstrong; Sarath Ranganathan; Amit Kochar; Catherine Wilson; Shane George; Natalie Phillips; Jeremy Furyk; Ben Lawton; Meredith L Borland; Sharon O'Brien; Jocelyn Neutze; Anna Lithgow; Clare Mitchell; Nick Watkins; Domhnall Brannigan; Joanna Wood; Charmaine Gray; Stephen Hearps; Emma Ramage; Amanda Williams; Jamie Lew; Leonie Jones; Andis Graudins; Stuart Dalziel; Franz E Babl Journal: BMJ Open Respir Res Date: 2022-03
Authors: Suzanne Schuh; Stephen B Freedman; Roger Zemek; Amy C Plint; David W Johnson; Francine Ducharme; Jocelyn Gravel; Graham Thompson; Sarah Curtis; Derek Stephens; Allan L Coates; Karen J Black; Darcy Beer; Judy Sweeney; Maggie Rumantir; Yaron Finkelstein Journal: JAMA Netw Open Date: 2021-07-01